Journal
DIABETES
Volume 63, Issue 10, Pages 3346-3358Publisher
AMER DIABETES ASSOC
DOI: 10.2337/db14-0302
Keywords
-
Categories
Funding
- Ministerio de Economia y Competitividad [BFU2011-29102, RYC-2008-02219, BFU2012-35255]
- Xunta de Galicia [10PXIB208164PR, 2012-CP070, EM 2012/039, 2012-CP069]
- Fondo de Investigaciones Sanitarias [PI12/01814, FISPI12/00515]
- CIBERobn
- FEDER (European Fund for Regional Development) funds
- European Community [245009]
- ERC [StG-2011-0BES111/53-281408]
Ask authors/readers for more resources
GLP-1 receptor (GLP-1R) is widely located throughout the brain, but the precise molecular mechanisms mediating the actions of GLP-1 and its long-acting analogs on adipose tissue as well as the brain areas responsible for these interactions remain largely unknown. We found that central injection of a clinically used GLP-1R agonist, liraglutide, in mice stimulates brown adipose tissue (BAT) thermogenesis and adipocyte browning independent of nutrient intake. The mechanism controlling these actions is located in the hypothalamic ventromedial nucleus (VMH), and the activation of AMPK in this area is sufficient to blunt both central liraglutide-induced thermogenesis and adipocyte browning. The decreased body weight caused by the central injection of liraglutide in other hypothalamic sites was sufficiently explained by the suppression of food intake. In a longitudinal study involving obese type 2 diabetic patients treated for 1 year with GLP-1R agonists, both exenatide and liraglutide increased energy expenditure. Although the results do not exclude the possibility that extrahypothalamic areas are also modulating the effects of GLP-1R agonists, the data indicate that long-acting GLP-1R agonists influence body weight by regulating either food intake or energy expenditure through various hypothalamic sites and that these mechanisms might be clinically relevant.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available